Online inquiry

IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2247MR)

This product GTTS-WQ2247MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Lama glama
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2247MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5978MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ5743MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10822MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ3204MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ12063MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ9959MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ14445MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ2854MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-570
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW